Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma: results of a pilot study

Am J Clin Oncol. 2000 Jun;23(3):288-9. doi: 10.1097/00000421-200006000-00016.

Abstract

We report the results of a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and folinic acid in patients with metastatic renal cell carcinoma. The objective of this pilot study was to define the potential efficacy of this second-line combination in patients previously treated with interleukin-2 alone or in combination with interferon alpha. Fourteen patients with metastatic renal cell carcinoma in failure after immunotherapy were included in this trial. During treatment, patients received six chemotherapy courses (Folfox regimen) administered every 2 weeks. Each cycle combined oxaliplatin day (D) D1 and folinic acid plus 5-fluorouracil D1 and D2. At completion of treatment, no objective response was observed and two patients presented stable disease. This chemotherapy schedule in patients with metastatic renal cell carcinoma previously treated with immunotherapy does not seem to be effective.

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma / drug therapy*
  • Carcinoma / secondary
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Immunotherapy
  • Interferon-alpha / therapeutic use
  • Interleukin-2 / therapeutic use
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / secondary
  • Leucovorin / administration & dosage
  • Male
  • Middle Aged
  • Organoplatinum Compounds
  • Pilot Projects
  • Prognosis

Substances

  • Interferon-alpha
  • Interleukin-2
  • Organoplatinum Compounds
  • Leucovorin
  • Fluorouracil

Supplementary concepts

  • Folfox protocol